Halozyme to Present Virtually at the 40th Annual J.P. Morgan Health Care Conference

Rhea-AI Summary

Halozyme Therapeutics (NASDAQ: HALO) announced that Dr. Helen Torley, CEO, will present virtually at the 40th Annual J.P. Morgan Health Care Conference on January 10, 2022, at 7:30 a.m. PT. The conference runs from January 10-13, 2022. Interested parties can access the presentation via the Investors section of Halozyme's website. Halozyme specializes in biopharmaceutical solutions, particularly its ENHANZE® technology, which enhances drug delivery efficiency and has reached over 500,000 patients globally.

SAN DIEGO, Jan. 4, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Dr. Helen Torley, president and chief executive officer, will present virtually at the 40^th Annual J.P. Morgan Health Care Conference on Monday, January 10, 2022 at  7:30 a.m. PT/ 10:30 a.m. ET. The virtual conference will be held from January 10-13, 2022.

A direct link to the presentations can be accessed through the "Investors" section of www.halozyme.com, and a recording will be made available for a limited time following the event. To access the link, please visit Halozyme's website approximately 10 minutes prior to the presentation to register and download any necessary audio software.

About Halozyme
Halozyme is a biopharmaceutical company bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. Halozyme advises and supports its biopharmaceutical partners in key aspects of new drug development with the goal of improving patients' lives while helping its partners achieve global commercial success. As the innovators of the ENHANZE^® technology, which can reduce hours-long treatments to a matter of minutes, Halozyme's commercially-validated solution has touched more than 500,000 patient lives in post-marketing use via five commercialized products across more than 100 global markets. Halozyme and its world-class partners are currently advancing multiple therapeutic programs intended to deliver innovative therapies, with the potential to improve the lives of patients around the globe. Halozyme's proprietary enzyme rHuPH20 forms the basis of the ENHANZE^® technology and is used to facilitate the delivery of injected drugs and fluids, potentially reducing the treatment burden of other drugs to patients. Halozyme has licensed its ENHANZE^® technology to leading pharmaceutical and biotechnology companies including Roche, Baxalta, Pfizer, AbbVie, Lilly, Bristol-Myers Squibb, Alexion, argenx, Horizon Therapeutics and ViiV Healthcare. Halozyme derives revenues from these collaborations in the form of milestones and royalties as the Company's partners make progress developing and commercializing their products being developed using ENHANZE^®. Halozyme is headquartered in San Diego. For more information visit Halozyme.com and connect with us on LinkedIn and Twitter.

Contact:
Al Kildani
Vice President, Investor Relations and Corporate Communications
858-704-8122
ir@halozyme.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/halozyme-to-present-virtually-at-the-40th-annual-jp-morgan-health-care-conference-301453276.html

SOURCE Halozyme Therapeutics, Inc.

FAQ

When is Halozyme's presentation at the J.P. Morgan Health Care Conference?

Halozyme's presentation is on January 10, 2022, at 7:30 a.m. PT.

What is the focus of Halozyme's ENHANZE technology?

ENHANZE technology aims to improve drug delivery efficiency, reducing treatment time from hours to minutes.

How many patients have benefited from Halozyme's technology?

Over 500,000 patients have benefited from Halozyme's technology in post-marketing use.

Where can I watch Halozyme's presentation?

You can watch it through the Investors section on Halozyme's website.

What dates does the J.P. Morgan Health Care Conference take place?

The conference runs from January 10-13, 2022.